T he inflammatory bowel diseases (IBD), 3 including both Crohn's disease and ulcerative colitis, are debilitating diseases of unknown etiology (1) . The most recent evidence suggests that IBD likely results from dysregulated immune responses to luminal triggers (1) . Human IBD has benefited immensely from the development of a number of investigational models to study disease pathogenesis (2) . Studies in animal models of IBD, primarily murine colitis models, have identified both pathological disease markers as well as endogenously protective molecules that promote the resolution of ongoing inflammation (2) . One such molecule of intense recent interest in IBD and other inflammatory diseases is the purine adenosine (Ado) (3) (4) (5) . A number of studies have indicated that Ado and its analogs can ameliorate the course of a variety of inflammatory diseases, including IBD (3, 5) . Depending on the target receptor (see below), Ado has also been demonstrated to either not influence disease outcome (6) or exacerbate inflammation in some models (7) .
Although the source of interstitial Ado in inflammation has been the basis of some debate, it is now appreciated that inhibition of Ado kinase and the dephosphorylation of ATP and AMP by surface apyrases (e.g., CD39) and ecto-5Ј-nucleotidase (CD73), respectively, represent the major pathways of extracellular Ado (8 -10) . Once liberated in the extracellular space, Ado is either recycled (e.g., through dipyridamole-sensitive carriers) or interacts with cell surface Ado receptors (11) . Presently, four subtypes of G protein-coupled Ado receptors exist, designated Ado A1 receptor (AA1R), Ado A1 receptor (AA2AR), Ado A2 receptor (AA2BR), or Ado A3 receptor (AA3R), and are classified according to utilization of pertussis toxin-sensitive (A1 and A3) or -insensitive (A2A and A2B) pathways (11) . Recent work has specifically implicated the AA2BR in anti-inflammatory responses, wherein activation of this receptor elicits potent inhibition of inflammatory signaling cascades mediated by NF-B (12) .
In this study, we sought to investigate the role of AA2BR in a model of murine colitis. Initial studies identified high expression of AA2AR and AA2BR in colonic mucosa. Studies with Aa2ar Ϫ/Ϫ and Aa2br Ϫ/Ϫ mice identified significantly increased susceptibility of the Aa2br Ϫ/Ϫ genotype. At multiple levels, Aa2br Ϫ/Ϫ mice were unable to mount effective responses to DSS-induced colitis. Similar findings were observed in wild-type animals administered the AA2BR antagonist PSB1115. Cytokine profiling of mucosal tissue identified specific deficiencies in IL-10 by AA2BR-deficient mucosa generated, at least in part, by colonic epithelial cells.
Materials and Methods

Ado receptor-deficient mice
Mice with homozygous deficiency for Aa2ar (Aa2ar Ϫ/Ϫ ) or Aa2br (Aa2br Ϫ/Ϫ ) on the C57BL/6 SVJ strain were generated and characterized as previously described (13) and maintained as homozygous crosses. Control C57BL/6 mice (Aa2br ϩ/ϩ ) were matched for age and gender in each experiment. All procedures involving animals were performed according to National Institutes of Health guidelines for use of live animals and were approved by the Institutional Animal Care and Use Committee at the University of Colorado and the University of Tuebingen.
DSS colitis model
DSS colitis was induced with a modification of the technique of Okayasu et al. (14) . Colitis was induced on day 0 by the addition of 2.5% DSS (m.w. ϭ 36,000 -50,000; MP Biomedicals) solution in drinking water. Control animals received water alone. Only animals that showed an initial response to DSS treatment, defined by at least a 5% weight loss relative to baseline weight, were included in the weight loss analysis for the DSS treatment groups. For these studies, 1 animal (of 53 induced) was excluded under these criteria.
PSB1115 and colitis
In subsets of experiments, mice were treated with the AA2BR inhibitor, PSB1115 (Tocris) was prepared at a concentration of 100 g/ml PBS, and animals were dosed by gavage with PSB1115 at 1 mg/kg every other day starting on day Ϫ1. In DSS experiments, PSB1115 treatment was initiated on the day Ϫ1, 1 day before the induction of colitis. Mice were then treated every second day until harvest on day 6 (four total doses). Control animals received corresponding volumes of PBS.
Disease activity index
Macroscopic symptoms of inflammation (stool consistency, presence of blood in stool, presence of blood at the anus, presence of relieving posture, and appearance of the fur) was assessed daily during the course of the experiment. The following scores were given to stool consistency: 0, formed stool; 1, formed and soft stool; and 3, diarrhea. For blood in stool: 0, no presence of fecal blood; and 3, presence of fecal blood. Anal blood score: 0, no blood; 1, inflamed anus; 2, slight bleeding; and 3, bleeding and edema. Relieving posture was scored with 0 -3 points, and unkempt fur was given 1 point. The scores were added, and the disease activity index was calculated. Maximum possible score was 10.
Histological scoring
Histological examination was performed on three samples of the distal colon. Samples were fixed in 10% formalin before staining with H&E. All histological quantitation was performed in a blinded fashion, using a previously described scoring system (15) Severity of inflammation: rare inflammatory cells in the lamina propria (0); increased numbers of inflammatory cells (1); confluence of inflammatory cells extending into the submucosa (2); and transmural extension of the inflammatory cell infiltrate (3). Extent of injury: nil mucosal damage (0); discrete lymphoepithelial lesions (1); surface mucosal erosion (2); and widespread mucosal ulceration and extension through deeper bowel wall structures (3). The scores of the two parameter were added, and the mean was calculated. Maximum possible score was 3.
Tissue cytokine profiling
Where indicated, Th1 and Th2 cytokine levels were screened from colonic tissue derived from Aa2br ϩ/ϩ or Aa2br Ϫ/Ϫ mice. Colon samples (50 mg) were homogenized for 10 s in lysis buffer (150 mM NaCL, 20 mM Tris (pH 7.5), 1 mM EDTA, 1 mM EGTA, 0.1% SDS, protease inhibitor mixture (Roche), phosphatase inhibitors 1 and 2 (Sigma-Aldrich), and 2 mM PMSF) at 4°C. Samples were cleared by centrifugation, and supernatants were assayed for indicated cytokines by chemiluminescence-based sandwich immunoassay (Meso Scale Diagnostics) according to the manufacturer's protocols. Plates were analyzed on a Sector 2400 Imager (Meso Scale Diagnostics). Where indicated, phospho-Akt was measured in a similar manner using chemiluminescence-based sandwich immunoassay (Meso Scale Diagnostics) according to the manufacturer's protocols.
Analysis of mRNA expression
RNA was isolated for transcriptional analysis from colonic mucosal scrapings homogenized in TRIzol (Invitrogen) using a 550 sonic dismembrator (Fisher Scientific International), followed by phenol-chloroform extraction, as described previously (16) . Reverse transcription was done using iScript cDNA synthesis kit using the manufacturer's instructions (Bio-Rad).
Real-time PCR was employed using iQ SYBR mix (iCycler; Bio-Rad), as described previously (17) . Primer sets were as follows: murine ␤-actin (sense primer, 5Ј-CTC TCC CTC ACG CCA TCC TG-3Ј, and antisense primer, 5Ј-TCA CGC ACG ATT TCC CTC TCA G-3Ј, 124 bp); murine AA2AR (sense primer, 5Ј-CCG AAT TCC ACT CCG GTA CA-3Ј, and antisense primer, 5Ј-CAG TTG TTC CAG CCC AGC AT-3Ј, 120 bp); and murine AA2BR (sense primer, 5Ј-TCT TCC TCG CCT GCT TCG T-3Ј, and antisense primer, 5Ј-CCA GTG ACC AAA CCT TTA TAC CTG A-3Ј, 121 bp). The final reaction volume (25 l) consisted of 12.5 l of SYBR Green I (Bio-Rad), 2.5 l of diluted cDNA, and 200 nM of each primer. Reaction cycle consisted of 95°C for 2 min, followed by 45 cycles of 95°C for 15 s, 62°C for 20 s and 72°C for 35 s, and a final extension at 72°C for 3 min.
FIGURE 1.
Mucosal adenosine receptor expression and influence of genotype on DSS colitis outcomes. Colonic mucosal scrapings derived from wild-type mice were initially screened for expression of adenosine receptor subtypes by conventional PCR (A, representative image from n ϭ 8) and for AA2AR and AA2BR by real-time PCR (B, n ϭ 8 animals/condition). Data were normalized to ␤-actin. In C and D, mice deficient in Aa2br (n ϭ 14, three relicates) or Aa2ar (n ϭ 5, two relicates) were compared with wild-type controls (n ϭ 13 and 5, respectively) in DSS colitis protocols as described in Materials and Methods. Shown here are weight loss curves following induction of DSS colitis (day 0), where ‫ء‬ indicates p Ͻ 0.01.
Cell culture and IL-10 measurements
Caco-2 cells were grown on permeable 5-cm 2 polycarbonate ring supports (Costar) to high confluence, using previously described protocols (18) . Where indicated, Caco2 cells were exposed to the Ado analog N-ethylcarbamido-Ado (NECA) for 48 h. Media were harvested, filtered, and assayed for IL-10 levels by electrochemiluminescence-based sandwich immunoassay (Meso Scale Diagnostics) according to the manufacturer's protocols. Plates were analyzed on a Sector 2400 Imager (Meso Scale Diagnostics).
Statistical analysis
Statistical analysis was performed using Student's t test or ANOVA, as indicated.
Results
Expression pattern of Ado receptors in murine mucosa
Extracellular Ado signaling has been widely implicated in adaptive responses to inflammation (19) . Previous studies have revealed that AA2BR is abundantly expressed on human intestinal epithelial cells (20) , and that such expression is regulated by hypoxiainducible factor-1 (17) . We therefore sought to define the contribution of AA2BR to colitic disease. Initially, we examined Ado receptor mRNA expression in mucosal scrapings (enriched in epithelial cells) from wild-type C57BL/6 mice. As shown in Fig. 1 , A and B, this analysis revealed expression of both AA2AR and AA2BR in mucosal scrapings. Such findings are consistent with previous studies in human epithelia (20) and therefore compelled us to examine how the Ado receptors contribute to mucosal inflammation, as modeled by DSS colitis.
Increased susceptibility of Aa2br
Ϫ/Ϫ mice to DSS colitis Based on the finding that murine intestinal epithelia express AA2AR and AA2BR, we subjected Aa2ar Ϫ/Ϫ and Aa2br Ϫ/Ϫ mice to DSS protocols and compared their responses to littermate wildtype controls. Our previous studies revealed that neither Aa2ar
Ϫ/Ϫ animals manifest outward immunological defects when housed in specific pathogen-free conditions (13) . In this study, we compared the clinical course of DSS-induced colitis in Aa2ar Ϫ/Ϫ and Aa2br Ϫ/Ϫ mice. Initial studies using 3.5% DSS revealed that Aa2br Ϫ/Ϫ mice became profoundly ill within 3 days of induction and resulted in high mortality (data not shown). For this reason, we decreased drinking water DSS concentrations to 2.5%. This comparison between Aa2ar Ϫ/Ϫ and Aa2br Ϫ/Ϫ is shown in Fig. 1 , C and D, respectively. Weight loss is a reliable method to assess DSS colitis severity (14) , and as shown in Fig. 1C , Aa2br Ϫ/Ϫ mice exposed to DSS lost weight more rapidly and failed to regain weight over the 6 days following induction of colitis ( p Ͻ 0.01 by ANOVA; Fig.  1C ). By comparison, Aa2ar Ϫ/Ϫ animals remained healthy at 2.5% DSS with no significant differences observed in weight loss curves between Aa2ar
Ϫ/Ϫ and littermate controls ( p ϭ not significant). Notably, Aa2ar
Ϫ/Ϫ mice showed increased susceptibility to higher concentrations of DSS. Indeed, when DSS concentrations were Ϫ/Ϫ showed significantly increased weight loss on days 2-6 (maximal difference 12 Ϯ 4% at day 5, p Ͻ 0.05 by ANOVA) and increased colon contraction (31 Ϯ 5% decrease in colon length, p Ͻ 0.05) compared with wild-type controls (n ϭ 4/group). Thus, it would appear that both Aa2ar Ϫ/Ϫ and Aa2br Ϫ/Ϫ mice have increased susceptibility to DSS colitis but that this phenotype is more severe in Aa2br Ϫ/Ϫ . Additional endpoints including disease activity index over the course of colitis ( Fig. 2A) and colon contraction at harvest (Fig.  2B ) also revealed significantly increased disease severity in Aa2br Ϫ/Ϫ mice compared with controls. Histologically, Aa2br
mice showed a prominent loss of tissue architecture and fulminant leukocyte infiltration compared with Aa2br ϩ/ϩ (Fig. 2, C and D) . In this regard, the AA2BR has been broadly implicated in inflammation associated with murine myocardial ischemia (21, 22) , ischemic preconditioning of the kidneys (23) , and acute lung injury (24) , wherein mechanisms have been tracked to inhibition of NF-B through Ado-mediated cullin deneddylation (12) . Thus, we determined whether colonic tissue from Aa2br Ϫ/Ϫ showed increased NF-B activation. Initial studies to document direct NF-B activity in colonic tissue proved technically difficult, and we therefore addressed signaling pathways upstream of NF-B. In particular, activity levels of the PI3K-Akt pathway, which critically regulates NF-B (25) proved interesting. As shown in Fig.  2E , levels of activated Akt (phospho-Akt) were significantly elevated over vehicle controls in both colitic Aa2br ϩ/ϩ and in Aa2br Ϫ/Ϫ ( p Ͻ 0.01 for both). Notably, colitic Aa2br Ϫ/Ϫ mice showed increased phospho-Akt levels compared with their wildtype counterparts ( p Ͻ 0.025). No differences were noted between Aa2br Ϫ/Ϫ and Aa2br Ϫ/Ϫ in baseline phospho-Akt levels. Such findings strongly implicate a protective role for AA2BR in experimental colitis.
Selective inhibition of AA2BR worsens the course of colitis
To rule out the possibility that increased susceptibility of Aa2br Ϫ/Ϫ mice to colitis could be attributable to a developmental etiology, we determined whether this phenotype could be mimicked by pharmacologic blockade of AA2BR using the selective inhibitor PSB1115 (26) . For these purposes, Aa2br ϩ/ϩ mice were administered PSB1115 (1 mg/kg) by gavage, a concentration we have previously shown to effectively inhibit AA2BR in a systemic fashion (13) . Mice were then subjected to DSS colitis with or without PSB1115 administered by gavage beginning on day Ϫ1 and then every second day (for a total of four doses) until harvest mice, wild-type PSB1115-treated mice exposed to DSS lost weight more rapidly and failed to show recovery weight gain during the course of the experiment ( p Ͻ 0.05 by ANOVA), compared with mice receiving DSS alone (Fig. 3A) . Likewise, other disease markers, including disease activity index (Fig. 3B ), colon length (Fig.  3C) , and histological scores (Fig. 3, D and E) , reflected worsened disease in those animals receiving PSB1115. Such findings confirm that altered AA2BR activity likely explains our findings of increased susceptibility in Aa2br Ϫ/Ϫ animals.
Loss of mucosal IL-10 expression in Aa2br Ϫ/Ϫ mice
In an attempt to gain specific insight into potential mechanisms of increased colitis susceptibility of Aa2br Ϫ/Ϫ mice, we profiled the expression of colon Th1 and Th2 immunoregulators following DSS colitis (day 6) in Aa2br Ϫ/Ϫ and Aa2br ϩ/ϩ mice (n ϭ 5 animals/group). This analysis was insightful inasmuch as it revealed that Aa2br Ϫ/Ϫ colons specifically express decreased amounts of IL-10. Indeed, as shown in Fig. 4, A 
Ado regulates intestinal epithelial-derived IL-10 in an AA2BR-dependent manner
We next extended these findings to a cultured human epithelia model. In this study, we examined whether cultured human intestinal epithelial cells (Caco2) respond to Ado through induction of IL-10. Intestinal epithelial cells are know to express high levels of AA2BR, particularly on the apical plasma membrane (20) . As shown in Fig. 5 , we exposed intestinal epithelial cells to the stable Ado analog NECA and examined IL-10 protein levels. Apical, but not basolateral, NECA induced a concentration-dependent increase in IL-10 protein ( p Ͻ 0.025 by ANOVA; Fig. 5A ). Maximal levels of soluble IL-10 were 21.5 Ϯ 4.2 pg/ml with the addition of NECA (1 M). To define the relative contribution of AA2BR to IL-10 induction, we used PSB1115 in combination with NECA. As shown in Fig. 5B, PSB1115 (1 M) attenuated NECA-induced IL-10 expression by 63 Ϯ 7% ( p Ͻ 0.025), thereby strongly implicating epithelial AA2BR in Ado-mediated IL-10 production.
Discussion
Extracellular Ado signaling has been widely implicated as an endogenous protective mechanism for a number of inflammatory diseases (19) . The studies presented here indicate that AA2BR expression inversely correlates with colitis severity. Indeed, elimination of functional AA2BR, either by genetic mutation in the Aa2br Ϫ/Ϫ mice or pharmacologic inhibition with PSB1115, results in an exacerbation of the acute inflammatory phase of DSS colitis. Additional markers of inflammation, including colonic shortening and histologic examination of colonic mucosal polymorphonuclear leukocyte infiltration, also support the finding of a more severe acute inflammatory response in the Aa2br Ϫ/Ϫ mice and therein To date, the AA2BR has not been defined in detail with regard to inflammatory models. One study addressed the role of AA2AR in murine diabetes models (27) . In particular, they showed that the NECA-induced suppression of immune-mediated hyperglycemia could be reversed with the AA2BR antagonist MRS1754, implicating (27) a specific role for AA2BR in immune suppression. Other studies have detailed the role of Ado receptor signaling in multiple experimental models of colitis resulting from a variety of methods of induction of inflammation. Using a T cell transfer model, Naganuma et al. (28) demonstrated that AA2AR appear to block the production of proinflammatory cytokines and that AA2AR agonists attenuate T cell-mediated colitis. Additional work has revealed a protective role for AA2AR in various other colitic models (29, 30) . One recent study (31) identified overexpression of AA2BR in experimental colitis, and two additional reports, one by Guzman et al. (32) .
Gusing a rat colitis model (32) and another by Mabley et al. (33) studying two independent mouse models of colitis, have indicated a protective role for the AA3R. Taken together, these findings suggest a more universal role for Ado receptor signaling in the resolution of colitis.
Our rationale for focusing on AA2BR in colitis was 3-fold. First, intestinal epithelial cells provide a first line of defense during colitis and coordinate mucosal inflammation at a number of levels (1). Because human intestinal epithelial cells prominently express AA2BR (20) , we reasoned that Ado signaling at the level of the epithelium may contribute to disease severity. An initial screen of murine colonic scrapings (enriched by Ͼ70% in epithelial cells (34) ) revealed that mouse colonic epithelia appear to express nearly equivalent levels of AA2AR and AA2BR, and essentially no detectable AA1R or AA3R. In this regard, Selmeczy et al. (6) showed that the AA2AR agonist CGS 21680 fails to ameliorate murine DSS colitis, thereby placing the AA2BR as an interesting target in colitis. Second, AA2BR expression, specifically on the intestinal epithelium, is dynamically regulated by inflammatory conditions found at colitic lesion sites (31) . Moreover, metabolic changes associated with colitis, including hypoxia, have been shown to induce epithelial and endothelial AA2BR (17) . Mechanisms of such regulation occur through transcription-dependent pathways involving hypoxia-inducible factor-1(17), a transcription factor expressed in intestinal epithelia and previously shown to be protective for colitis (16) . Third, the recent generation of Aa2br Ϫ/Ϫ mice has provided opportunities to define the contribution of AA2BR in various models of inflammation. A primary endpoint to Ado receptor activation, including AA2BR, has been barrier function. In vitro and in vivo studies dating back more than a decade have implicated Ado and AA2BR as a mechanism to promote epithelial restitution and tight junction resealing (10, 35) , as well as promoting endothelial barrier function (9, 36) . These studies revealed that Ado signals to the tight junction via phosphorylation of the actin-binding protein vasodilator-stimulated phosphoprotein (37, 38) . More recent studies have clearly defined a protective role for AA2BR in hypoxia and inflammation-based disease models, including vascular leak syndromes (13) . Thus, given the importance of barrier function to mucosal inflammation, we hypothesized a role for AA2BR in a murine model of colitis.
Initial studies suggested that intestinal epithelial cells express mRNA for both AA2AR and AA2BR. On the basis of these findings, we used the DSS colitis model to define the contribution of these receptors to disease outcome. Studies with Aa2ar Ϫ/Ϫ and Aa2br Ϫ/Ϫ mice under similar conditions (2.5% DSS) revealed that Aa2br Ϫ/Ϫ mice are profoundly more susceptible to DSS-based colitis. It should be noted that these studies have not defined precise details regarding the contribution of the Aa2ar genotype to DSS colitis, but our studies also suggest that Aa2ar Ϫ/Ϫ also show increased susceptibility to DSS colitis. Indeed, conditions that would likely result in more severe disease in Aa2ar Ϫ/Ϫ mice (e.g., 4.5% DSS) revealed profound disease with high mortality in Aa2br Ϫ/Ϫ mice and increased susceptibility of Aa2ar Ϫ/Ϫ compared with Aa2ar ϩ/ϩ . Although we do not know the exact basis of these differences between Aa2ar
Ϫ/Ϫ and Aa2br Ϫ/Ϫ , it could be explained by the distribution of these receptors within the colon. For example, although both AA2AR and AA2BR appear to be expressed on leukocyte populations, epithelial cells express primarily AA2BR and this receptor is induced during colitis (39) . Because DSS colitis, in particular, functions as an epithelial irritant, it is possible that this phenotype is explained more by the expression of AA2BR on the epithelium. On the basis of these initial findings, we further detailed DSS colitis in the Aa2br Ϫ/Ϫ genotype. Multiple levels of analysis, including body weight loss, disease activity index, histology, and colon length revealed significantly more disease in Aa2br Ϫ/Ϫ mice. Importantly, this increased disease severity is not likely to be related to a developmental issue of the Aa2br Ϫ/Ϫ genotype. In particular, these results are, at least in part, recapitulated by the systemic administration of the AA2BR antagonist PSB1115 in wild-type mice. Such results implicate a specific role for AA2BR in DSS-based colitis.
Profiling of cytokine levels from colons derived from Aa2br
and Aa2br Ϫ/Ϫ animals revealed that the loss of AA2BR is closely linked to specific reductions in the levels of IL-10, suggesting a relationship between AA2BR activity and downstream regulation of IL-10 expression. These findings were further supported by the demonstration that the pharmacologic inhibition of AA2BR activity also leads to down-regulation of IL-10 protein expression in human intestinal epithelia. Clear evidence supports a role for IL-10 in colonic inflammation (1). IL-10-deficient mice are well-established murine models of IBD and are known to develop spontaneous chronic enterocolitis (40) . Furthermore, IL-10 levels have been demonstrated to increase both in colonic tissue in experimental models of colitis (41) and in serum from human patients with active ulcerative colitis and in the recovery phase of both ulcerative colitis and Crohn's Disease (42) . Here we demonstrate a role for AA2BR-mediated IL-10 in response to colonic inflammation in the setting of DSS colitis in vivo and in response to exogenous Ado in vitro. These studies are in line with recent work ecto-5Ј-nucleotidase (CD73) in murine colitis (34) , wherein animals genetically deficient in the terminal enzyme for extracellular Ado production (CD73) showed increased susceptibility to haptenbased colitis. Similar to our findings here, these animals lacked the capacity to make normal levels of IL-10 in response to colitis. We do not currently know exact mechanisms of Ado-mediated IL-10 induction. The AA2BR is a G␣s protein-coupled receptor tightly linked elevations in intracellular cyclic AMP (11) . It is possible, therefore, that Ado could directly activate the IL-10 promoter, particularly since IL-10 has a well-established regulatory response to the transcription factor cyclic AMP response element binding protein (43, 44) . Alternatively, induction of IL-10 could occur through alternative pathways. For example, Nemeth et al. (45) has demonstrated that Ado augments macrophage IL-10 through an AA2BR-mediated posttranscriptional pathway involving the 3Ј-untranslated region of the IL10 gene. Of note, in the current studies, we have not precisely localized the source of IL-10 in the colon. Epithelial isolations are sufficiently contaminated to disallow specific conclusions. We presume, based on our data obtained from human epithelial cells, that IL-10 is derived from colonic epithelia but that other sources exist. Indeed, although IL-10 can be made by most any nucleated cells (46) , including intestinal epithelial cells (47) , leukocyte subpopulations are a major source of IL-10 (46). It is possible, therefore, that IL-10 could be derived from more than one source in these studies.
In contrast to the findings of the present studies, a recent study suggests proinflammatory role of A2BAR signaling in murine colitis (39) . Consistent with our studies, the authors found that the A2BAR is the predominant Ado receptor expressed in the colonic epithelia. However, when exposing mice to DSS-induced colitis, they found that mice with genetic deletion of the A2BAR are protected and mucosal inflammation is attenuated. Why the result from this study (39) is different from the present studies is not clearly understood. In contrast to the study by Kolachala et al. (39) , several previous studies support an anti-inflammatory and tissue protective role of A2BAR signaling in different organ systems. For example, gene-targeted mice for the A2BAR show enhanced vascular inflammation when exposed to endotoxin (48) or during acute vascular injury (49) . Similarly, gene-targeted deletion of the A2BAR is associated with enhanced vascular leakage and inflammation during ambient hypoxia (9, 13) . In addition, studies of murine myocardial ischemia (21, 22) , ischemic preconditioning of the kidneys (23), or during acute lung injury (24) provide convincing evidence for an anti-inflammatory and tissue-protective role of A2BAR signaling. Potential explanations why the studies of Kolachala et al. (39) found a detrimental role of A2BAR signaling during murine colitis could include details in the colitis protocol, differences in murine strains with genetic deletion of the A2BAR or differences in housing conditions, including differences in bacterial flora of the mice. However, it seems important to point out that in some of their studies-and in contrast to the overall theme of this article-gene-targeted for the A2BAR mice experienced a proinflammatory phenotype (39) . For example, A2BAR
Ϫ/Ϫ mice showed increased susceptibility to systemic Salmonella infection. In fact, 90% of A2BAR Ϫ/Ϫ mice died within 10 days compared with 20% of wild-type mice following orally administered Salmonella typhimurium. Consistent with the mortality data, A2BAR Ϫ/Ϫ mice also showed signs of weight loss earlier than wild-type mice (39) . Some additional comparisions between the individual mouse strains may be necessary to rectify some of these apparent discrepancies.
Taken together, our findings strongly implicate AA2BR as an endogenous mechanism of protection in a murine model of colitis. These studies identify IL-10 as a specific endpoint for regulated colitic responses and highlight the essential role of the epithelium in these responses. Further studies will be necessary to determine the underlying mechanisms of this response and whether AA2BR might be an attractive therapeutic target in mucosal diseases such as IBD.
Disclosures
The authors have no financial conflict of interest.
